Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Yee AJ, Laubach JP, Campagnaro EL, Lipe BC, Nadeem O, Friedman RS, Cole CE, O'Donnell E, Bianchi G, Branagan AR, Schlossman RL, Shaprio SJ, Harrington CC, Burke JN, Gammon MT, Lively KJ, Reimonn CA, Andrade DX, Redd RA, Lohr JG, Anderson KC, Richardson PG, Raje N.
Yee AJ, et al. Among authors: harrington cc.
Blood Adv. 2024 Dec 3:bloodadvances.2024014717. doi: 10.1182/bloodadvances.2024014717. Online ahead of print.
Blood Adv. 2024.
PMID: 39626297